

PACIRA – SHORT SUMMARY

Opioids add risk, impact recovery, and impose clinical and financial burdens. Overreliance on opioids—particularly in the postsurgical setting—can have unintended downstream consequences for patients, communities, and our nation’s overall societal well-being. Opioid addiction and reoccurrence are preventable. Non-opioid pain management treatments offer quality, evidence-based alternatives to opioid pain management.

Pacira Biosciences is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving patient outcomes. Our mission at Pacira is to offer an opioid alternative to as many patients as possible to reduce exposure and dependence on opioids. Unfortunately, patients are most often exposed to opioids after surgery, resulting in increased risk of addiction. This is preventable and there are non-opioid alternatives available such as EXPAREL.

EXPAREL is a non-opioid numbing medication (anesthetic) that is injected at the surgical site during surgery and numbs just the surgical site for about 3 days after the surgery. This has made it possible to greatly reduce, or in some cases eliminate the need for opioids after surgery. EXPAREL has been used in more than 10 million patients since 2012 and has been shown to:

- Significantly reduce opioid requirements while providing significant pain control^{1,2}
- Reduce opioid-related complications³
- Enable faster functional recovery⁴
- Reduce length of hospital stay³
- Allow for shift of procedures to outpatient settings⁵
- Help reduce costs when used in multimodal pain management^{6,7}

References

- 1. Mont KA, Beaver WB, Dysart SH, Barrington JW, Del Gaizo DJ. Local infiltration analgesia with liposomal bupivacaine improves pain scores and reduces opioid use after total knee arthroplasty: results of a randomized controlled trial. *J Arthroplasty*. 2018;33(1):90-96. doi:10.1016/j.arth.2017.07.024.**
- 2. Patel KA, Gadsden JC, Nedeljkovic SS, et al. Brachial plexus block with liposomal bupivacaine for shoulder surgery improves analgesia and reduces opioid consumption: results from a multicenter, randomized, double-blind, controlled trial. *Pain Med*. 2020;21(2):387-400.**
- 3. Hutchins J, Vogel RI, Chebre R, et al. Ultrasound-guided subcostal transversus abdominis plane infiltration with liposomal bupivacaine for patients undergoing robotic-assisted hysterectomy:**

a retrospective study. *Int J Gynecol Cancer*. 2015;25(5):937-941.

4. Yu S, Dundon J, Solovyova O, Bosco J, Iorio R. Can multimodal pain management in TKA eliminate patient-controlled analgesia and femoral nerve blocks? *Clin Orthop Relat Res*. 2018;476(1):101-109.

5. Stewart R. (2018). What CMS' decision to pay separately for Exparel use means for ASCs — 5 insights. Becker's ASC Review website. Published December 11, 2018. Accessed July 21, 2021.

<https://www.beckersasc.com/asc-coding-billing-and-collections/whatems-decision-to-pay-separately-for-exparel-use-means-for-asc-5-insights.html>.

6. Ballock RT, Seif J, Goodwin R, Lin JH, Cirillo J. Clinical and economic outcomes associated with use of liposomal bupivacaine versus standard of care for management of postsurgical pain in pediatric patients undergoing spine surgery. *J Health Econ Outcome Res*. 2021;8(1):29-35.

7. Cohen SM, Vogel JD, Harcet JE, Candiotti KA. Liposome bupivacaine for improvement in economic outcomes and opioid burden in GI surgery: IMPROVE study pooled analysis. *J Pain Res*. 2014;7:359-366.

8. Pacira Pharmaceuticals Inc. EXPAREL® (bupivacaine liposome) Injectable Suspension. [Prescribing Information]. Parsippany, NJ: Pacira Pharmaceuticals Inc.; Mar 2021 <https://www.exparel.com/hcp/prescriptioninformation.pdf>